BGC-20-1531 (PGN 1531) free base is a potent and specific prostaglandin EP4 receptor antagonist (inhibitor) with a pKB value of 7.6. BGC-20-1531 free base may be used for studying migraine.

Physicochemical Properties

Molecular Formula	C26H24N2O6S
Molecular Weight	492.5436
Exact Mass	492.135
CAS #	736183-35-0
Related CAS #	BGC-20-1531 hydrochloride;1962928-26-2
PubChem CID	18444613
Appearance	Light yellow to brown solid powder
LogP	4.5
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	8
Heavy Atom Count	35
Complexity	794
Defined Atom Stereocenter Count	0
SMILES	S(C1=C([H])C([H])=C([H])C([H])=C1C([H])([H])[H])(N([H])C(C1=C([H])C(C([H])([H])OC2C([H])=C([H])C(C3C([H])=C([H])C(=C([H])N=3)OC([H])([H])[H])=C([H])C=2[H])=C(C([H])([H])[H])O1)=O)(=O)=O
InChi Key	IXDVRRPNWPOPGV-UHFFFAOYSA-N
InChi Code	InChI=1S/C26H24N2O6S/c1-17-6-4-5-7-25(17)35(30,31)28-26(29)24-14-20(18(2)34-24)16-33-21-10-8-19(9-11-21)23-13-12-22(32-3)15-27-23/h4-15H,16H2,1-3H3,(H,28,29)
Chemical Name	4-[[4-(5-methoxypyridin-2-yl)phenoxy]methyl]-5-methyl-N-(2-methylphenyl)sulfonylfuran-2-carboxamide
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	EP4 7.6 (pKd)
ln Vitro	Human middle cerebral (pKb=7.8) and meningeal (pKb=7.6) arteries' PGE2-induced vasodilatation was competitively inhibited by BGC-20-1531 free base, whereas PGE2-induced responses in coronary, pulmonary, or renal arteries were unaffected[1].
ln Vivo	The dose-dependent inhibition of PGE2-induced increase in canine carotid blood flow is caused by BGC-20-1531 free base (1-10 mg/kg; iv)[1].
Animal Protocol	Animal/Disease Models: Beagle dogs[1] Doses: 1- 10 mg/kg Route of Administration: Iv Experimental Results: Caused a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow.
References	[1]. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009;156(2):316-327.
Additional Infomation	See also: Bgc-20-1531 (annotation moved to).

Solubility Data

Solubility (In Vitro)

DMSO: 250 mg/mL (507.57 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.08 mg/mL (4.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.0303 mL	10.1515 mL	20.3029 mL
	5 mM	0.4061 mL	2.0303 mL	4.0606 mL
	10 mM	0.2030 mL	1.0151 mL	2.0303 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.